Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial
Nicholas Govsyeyev(Meridian Clinical Research), Marc P. Bonaca(The Medical Center of Aurora), Manesh R. Patel(Duke University), Sarah Kavanagh(Meridian Clinical Research), Lars Norgren(Örebro University Hospital), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Juuso Blomster(AstraZeneca (Netherlands)), F. Gerry R. Fowkes(University of Edinburgh), Cecilia C. Low Wang(University of Colorado Anschutz Medical Campus), Philip P. Goodney(Dartmouth–Hitchcock Medical Center), Mark R. Nehler(Bühler (United Kingdom)), William R. Hiatt(University of Colorado Denver), Iris Baumgärtner(Hirslanden Klinik Beau-Site), Jeffrey S. Berger(New York University), Chandler A. Long(Duke University), Joshua A. Beckman(Clinical Research Institute), Brian G. Katona(AstraZeneca (Brazil)), W. Schuyler Jones(Duke University)
Cited by 13
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k